NanoSphere Health Sciences Inc. (NSHSF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -12.22 Thousand USD | 97.19% |
| 2022 | - USD | 26.31% |
| 2021 | -341.26 Thousand USD | 26.23% |
| 2020 | -529.77 Thousand USD | 83.04% |
| 2019 | -3.39 Million USD | 30.58% |
| 2018 | -4.24 Million USD | -290.33% |
| 2017 | -10.25 Million USD | -81.97% |
| 2016 | -512.93 Thousand USD | -540.03% |
| 2015 | -98.28 Thousand USD | 28.28% |
| 2014 | -220.13 Thousand USD | -103.17% |
| 2013 | -6.4 Million USD | 439.98% |
| 2012 | -3.64 Million USD | -143.02% |
| 2011 | -9.01 Million USD | 1604.66% |
| 2010 | -478.81 Thousand USD | -32.6% |
| 2009 | 162.07 Thousand USD | 97.44% |
| 2008 | -5.7 Million USD | -398.52% |
| 2007 | -1.04 Million USD | -3628.83% |
| 2006 | -31.15 Thousand USD | -22.82% |
| 2005 | -25.36 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -31.86 Thousand USD | 0.0% |
| 2024 Q2 | -56.7 Thousand USD | 0.0% |
| 2023 FY | - USD | 15.69% |
| 2023 Q3 | -63.86 Thousand USD | -14.26% |
| 2023 Q4 | -65.11 Thousand USD | -1.95% |
| 2023 Q1 | -53.91 Thousand USD | 61.36% |
| 2023 Q2 | -55.89 Thousand USD | -3.68% |
| 2022 Q3 | -1463.00 USD | 97.87% |
| 2022 FY | - USD | 26.31% |
| 2022 Q2 | -68.75 Thousand USD | 9.82% |
| 2022 Q1 | -76.24 Thousand USD | 77.35% |
| 2022 Q4 | -139.53 Thousand USD | -9437.87% |
| 2021 Q1 | -72.94 Thousand USD | 42.72% |
| 2021 Q2 | -164.5 Thousand USD | -125.53% |
| 2021 Q3 | 186.01 Thousand USD | 213.08% |
| 2021 FY | - USD | 26.23% |
| 2021 Q4 | -336.66 Thousand USD | -280.98% |
| 2020 FY | - USD | 83.04% |
| 2020 Q1 | -214.49 Thousand USD | 80.67% |
| 2020 Q2 | -116.26 Thousand USD | 45.79% |
| 2020 Q3 | -68 Thousand USD | 41.51% |
| 2020 Q4 | -127.34 Thousand USD | -87.26% |
| 2019 Q2 | -479.05 Thousand USD | 31.18% |
| 2019 Q4 | -1.1 Million USD | -35.8% |
| 2019 FY | - USD | 30.58% |
| 2019 Q1 | -696.1 Thousand USD | 64.66% |
| 2019 Q3 | -817.01 Thousand USD | -70.55% |
| 2018 FY | - USD | -290.33% |
| 2018 Q1 | -995.18 Thousand USD | -35.31% |
| 2018 Q4 | -1.96 Million USD | -180.1% |
| 2018 Q3 | -703.17 Thousand USD | 12.11% |
| 2018 Q2 | -800.07 Thousand USD | 19.61% |
| 2017 FY | - USD | -81.97% |
| 2017 Q4 | -735.47 Thousand USD | -730.82% |
| 2017 Q2 | -227.15 Thousand USD | -190.58% |
| 2017 Q1 | -78.17 Thousand USD | 5.07% |
| 2017 Q3 | -88.52 Thousand USD | 61.03% |
| 2016 Q3 | -465.52 Thousand USD | -838.42% |
| 2016 FY | - USD | -540.03% |
| 2016 Q1 | -32.78 Thousand USD | -143.45% |
| 2016 Q4 | -82.34 Thousand USD | 82.31% |
| 2016 Q2 | -49.6 Thousand USD | -51.29% |
| 2015 Q4 | -13.46 Thousand USD | 29.64% |
| 2015 Q3 | -19.14 Thousand USD | 53.98% |
| 2015 Q1 | -28.81 Thousand USD | -114.22% |
| 2015 Q2 | -41.59 Thousand USD | -44.35% |
| 2015 FY | - USD | 28.28% |
| 2014 FY | - USD | -103.17% |
| 2014 Q2 | -69.45 Thousand USD | -83.92% |
| 2014 Q1 | -37.76 Thousand USD | -105.7% |
| 2014 Q4 | 202.57 Thousand USD | 185.9% |
| 2014 Q3 | -235.82 Thousand USD | -239.56% |
| 2013 Q4 | 662.24 Thousand USD | 301.17% |
| 2013 Q3 | 165.07 Thousand USD | -95.58% |
| 2013 Q2 | 3.73 Million USD | 1291.34% |
| 2013 Q1 | -313.7 Thousand USD | -76.1% |
| 2013 FY | - USD | 439.98% |
| 2012 Q4 | -178.13 Thousand USD | 64.56% |
| 2012 FY | - USD | -143.02% |
| 2012 Q2 | -539.34 Thousand USD | -4348.67% |
| 2012 Q3 | -502.65 Thousand USD | 6.8% |
| 2012 Q1 | -12.12 Thousand USD | 98.36% |
| 2011 FY | - USD | 1604.66% |
| 2011 Q4 | -740.55 Thousand USD | -26.66% |
| 2011 Q1 | -1.02 Million USD | -1270.77% |
| 2011 Q2 | -926.42 Thousand USD | 10.04% |
| 2011 Q3 | -584.66 Thousand USD | 36.89% |
| 2010 FY | - USD | -32.6% |
| 2010 Q3 | -48.78 Thousand USD | -29.2% |
| 2010 Q2 | -37.76 Thousand USD | -15.58% |
| 2010 Q1 | -32.67 Thousand USD | -72.64% |
| 2010 Q4 | -75.12 Thousand USD | -53.99% |
| 2009 Q3 | -33.51 Thousand USD | 29.67% |
| 2009 FY | - USD | 97.44% |
| 2009 Q4 | -18.92 Thousand USD | 43.53% |
| 2009 Q2 | -47.64 Thousand USD | -27.48% |
| 2009 Q1 | -37.37 Thousand USD | -100.61% |
| 2008 FY | - USD | -398.52% |
| 2008 Q4 | 6.16 Million USD | 198.51% |
| 2008 Q3 | -6.26 Million USD | -4466.09% |
| 2008 Q2 | -137.1 Thousand USD | -18.02% |
| 2008 Q1 | -116.16 Thousand USD | 85.0% |
| 2007 Q4 | -774.26 Thousand USD | -165.98% |
| 2007 Q1 | -2091.71 USD | 85.71% |
| 2007 FY | - USD | -3628.83% |
| 2007 Q2 | -84.34 Thousand USD | -3932.37% |
| 2007 Q3 | -291.09 Thousand USD | -245.12% |
| 2006 Q2 | -6296.00 USD | 45.2% |
| 2006 Q4 | -14.64 Thousand USD | -385.84% |
| 2006 Q3 | -3013.61 USD | 52.13% |
| 2006 FY | - USD | -22.82% |
| 2006 Q1 | -11.48 Thousand USD | -216.91% |
| 2005 FY | - USD | 0.0% |
| 2005 Q3 | -21.95 Thousand USD | 0.0% |
| 2005 Q4 | -3625.09 USD | 83.49% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 99.983% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 99.794% |
| SQZ Biotechnologies Company | -64.14 Million USD | 99.981% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 99.93% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.013% |
| Mesoblast Limited | -62.38 Million USD | 99.98% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 99.204% |
| Genus plc | 73.7 Million USD | 100.017% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 99.815% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 99.655% |
| Marizyme, Inc. | -34.28 Million USD | 99.964% |
| ContraFect Corporation | -64.99 Million USD | 99.981% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 99.861% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 99.73% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 99.128% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 99.538% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 99.474% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 97.639% |
| Accustem Sciences Inc. | -3.74 Million USD | 99.674% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 99.975% |
| EV Biologics, Inc. | -1.26 Million USD | 99.035% |
| Q BioMed Inc. | -617.62 Thousand USD | 98.02% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 100.342% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 98.066% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 99.465% |
| Biomind Labs Inc. | -1.03 Million USD | 98.818% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 100.124% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 99.829% |
| Skye Bioscience, Inc. | -13.54 Million USD | 99.91% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 99.178% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 51.084% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 99.685% |
| IMV Inc. | -35.52 Million USD | 99.966% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 99.923% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 99.511% |
| GB Sciences, Inc. | -1.41 Million USD | 99.139% |
| Alpha Cognition Inc. | -9.7 Million USD | 99.874% |
| HST Global, Inc. | -5303.00 USD | -130.605% |
| CSL Limited | 4.78 Billion USD | 100.0% |
| Halberd Corporation | -74.27 Thousand USD | 83.536% |
| Enzolytics Inc. | -2.12 Million USD | 99.424% |
| Resverlogix Corp. | -11.74 Million USD | 99.896% |
| Affymax, Inc. | -14.29 Million USD | 99.914% |
| SYBLEU INC | -141.57 Thousand USD | 91.362% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 99.601% |
| argenx SE | -216.02 Million USD | 99.994% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 99.978% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 101.005% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 99.184% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 103.228% |
| AVAX Technologies, Inc. | -6.11 Million USD | 99.8% |
| Zenith Capital Corp. | -8.6 Million USD | 99.858% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.995% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 29.803% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 99.5% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 93.053% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 99.969% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 99.577% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 98.831% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 281.871% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 99.301% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 99.363% |
| BioStem Technologies, Inc. | -7.55 Million USD | 99.838% |
| ONE Bio Corp. | 13.61 Million USD | 100.09% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 93.247% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 99.405% |
| Agentix Corp. | -1.37 Million USD | 99.109% |
| LadRx Corporation | 412.28 Thousand USD | 102.966% |
| Cell Source, Inc. | -4.27 Million USD | 99.714% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 96.67% |
| Regen BioPharma, Inc. | 1.46 Million USD | 100.834% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 98.695% |
| NovAccess Global Inc. | -1.03 Million USD | 98.818% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 100.138% |
| Itoco Inc. | -1.86 Million USD | 99.346% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 96.779% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 98.904% |
| Kadimastem Ltd | -2.62 Million USD | 99.534% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 94.886% |
| CytoDyn Inc. | -18.02 Million USD | 99.932% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 84.526% |
| Mobile Lads Corp. | -2.24 Million USD | 99.454% |
| Qrons Inc. | -40.08 Thousand USD | 69.489% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 97.482% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 102.319% |
| Rebus Holdings, Inc. | -951 Thousand USD | 98.714% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 98.849% |
| International Stem Cell Corporation | 202 Thousand USD | 106.054% |
| Bioxytran, Inc. | -3.82 Million USD | 99.68% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 76.769% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 99.503% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 99.966% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | 72.824% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 99.553% |
| Neutra Corp. | -181.24 Thousand USD | 93.253% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 99.939% |
| PureTech Health plc | -11.62 Million USD | 99.895% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 99.939% |
| IXICO plc | -707 Thousand USD | 98.27% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 99.841% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 99.975% |
| CSL Limited | 4.73 Billion USD | 100.0% |
| Cellectis S.A. | -92.63 Million USD | 99.987% |